- Home
- APLM vs SMSI Comparison
APLM vs SMSI Comparison
Compare APLM & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- SMSI
- Stock Information
- Founded
- APLM 2016
- SMSI 1982
- Country
- APLM United States
- SMSI United States
- Employees
- APLM N/A
- SMSI N/A
- Industry
- APLM Blank Checks
- SMSI Computer Software: Prepackaged Software
- Sector
- APLM Finance
- SMSI Technology
- Exchange
- APLM Nasdaq
- SMSI Nasdaq
- Market Cap
- APLM 15.6M
- SMSI 16.2M
- IPO Year
- APLM N/A
- SMSI 1995
- Fundamental
- Price
- APLM $7.89
- SMSI $0.96
- Analyst Decision
- APLM Strong Buy
- SMSI Strong Buy
- Analyst Count
- APLM 2
- SMSI 1
- Target Price
- APLM $425.00
- SMSI $5.00
- AVG Volume (30 Days)
- APLM 106.0K
- SMSI 242.1K
- Earning Date
- APLM 08-14-2024
- SMSI 11-13-2024
- Dividend Yield
- APLM N/A
- SMSI N/A
- EPS Growth
- APLM N/A
- SMSI N/A
- EPS
- APLM N/A
- SMSI N/A
- Revenue
- APLM $2,101,000.00
- SMSI $24,178,000.00
- Revenue This Year
- APLM N/A
- SMSI N/A
- Revenue Next Year
- APLM N/A
- SMSI $62.34
- P/E Ratio
- APLM N/A
- SMSI N/A
- Revenue Growth
- APLM 70.54
- SMSI N/A
- 52 Week Low
- APLM $6.50
- SMSI $0.52
- 52 Week High
- APLM $105.00
- SMSI $7.52
- Technical
- Relative Strength Index (RSI)
- APLM 42.42
- SMSI 61.96
- Support Level
- APLM $7.70
- SMSI $0.72
- Resistance Level
- APLM $8.88
- SMSI $0.90
- Average True Range (ATR)
- APLM 1.34
- SMSI 0.10
- MACD
- APLM -0.04
- SMSI 0.03
- Stochastic Oscillator
- APLM 24.77
- SMSI 68.91
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.